TLDR: Waystar Holding Corp. has announced a definitive agreement to acquire Iodine Software for $1.25 billion. This strategic acquisition is set to significantly enhance Waystar’s artificial intelligence capabilities within healthcare payments and revenue cycle management, integrating Iodine’s advanced AI-powered clinical intelligence software. The transaction, expected to close by the end of 2025, will be financed through a combination of cash and stock and is anticipated to immediately improve Waystar’s financial performance.
Waystar Holding Corp., a prominent provider of healthcare payment software, has entered into a definitive agreement to acquire Iodine Software, an AI-driven clinical intelligence company, for a total enterprise value of $1.25 billion. The announcement, made on July 23, 2025, marks Waystar’s first major acquisition since going public last year and underscores its commitment to advancing AI in healthcare finance.
The acquisition aims to significantly bolster Waystar’s AI capabilities in healthcare payments and expand its market reach by over 15%. Iodine Software is renowned for its AI-powered software solutions designed to automate clinical administration and revenue cycle management. Its technology leverages proprietary AI models trained on one of the industry’s most extensive clinical datasets, reportedly representing more than a third of all U.S. inpatient discharges.
The transaction will be funded with an equal mix of cash and stock consideration. Upon the closing of the deal, current Waystar shareholders are projected to own approximately 92% of the combined company on a fully diluted, pro forma basis, while Iodine equity holders will hold approximately 8%. Advent International, Iodine’s largest shareholder, is expected to receive only Waystar shares and will be subject to an 18-month lock-up period post-closing.
Waystar executives anticipate that the acquisition will be immediately accretive to gross margin and adjusted EBITDA margin. Furthermore, it is expected to contribute positively to revenue growth and non-GAAP net income per diluted share starting in 2027. The integration of Iodine’s unique clinical data assets with Waystar’s expansive data network is poised to enhance the impact and reach of Waystar’s existing AI platform, AltitudeAI.
Strategically, the merger will add Iodine Software’s clinical intelligence capabilities to Waystar’s robust software suite. Waystar also expects to benefit from Iodine’s fully subscription-based revenue model and significant cross-sell potential across both companies’ client bases. The combined entity plans to launch new Generative AI (GenAI) applications aimed at streamlining critical healthcare payment processes, including prior authorizations, claims management and processing, denial prevention, and appeals.
Also Read:
- Craneware’s Trisus® Chargemaster Achieves Microsoft Solutions Partner Status for Healthcare AI, Bolstering Trust in Hospital Financial Automation
- Didero Expands AI Procurement Capabilities with Covalent AI Acquisition
Waystar currently serves approximately 30,000 clients and over 1 million providers, processing more than 6 billion healthcare payment transactions annually. This acquisition is a strategic move to further simplify healthcare payments and optimize financial performance for providers through advanced AI solutions. The deal is anticipated to close by the end of 2025, pending regulatory approvals.
